MIRA Pharmaceuticals develops oral ketamine and pharmaceutical marijuana analogs to treat neurologic and neuropsychiatric disorders.

MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company with two neuroscientific programs targeting a broad range of neurologic and neuropsychiatric disorders. Our novel oral pharmaceutical marijuana, MIRA-55, is currently under investigation for treating adult patients suffering from neuropathic pain, anxiety, and cognitive decline, often associated with early-stage dementia. We have an exclusive licensing agreement for Ketamir-2 (“Ketamir”), a unique, patent-pending novel oral ketamine analog under investigation to potentially deliver ultra-rapid antidepressant effects for patients who have not had a meaningful response to conventional treatments, providing new hope for individuals battling treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDSI).

MIRA Pharmaceuticals ( $MIRA)  Introduces Nor-Ketamir – an Extended Duration, Brain-Penetrating, and Selective Compound Targeting the NMDA PCP Receptor
https://lnkd.in/eg8xytGK
#stockstowatch #stocksinnews #investors #daytrader #PrismMarketView #PrismMediaWire #PrismDigitalMedia

🚀 $MIRA Exciting Developments at MIRA Pharmaceuticals! 🚀

We’re excited to share new preclinical data on Ketamir-2 and its principal metabolite Nor-Ketamir! This innovative compound is showing promising potential as a longer-acting, brain-penetrating, and highly selective treatment for neurological disorders.

Key Findings:

Enhanced Bioavailability: Nor-Ketamir demonstrates nearly 100% oral bioavailability in preclinical studies.

Prolonged Therapeutic Potential: Extended half-life and sustained brain penetration could make it suitable for at-home treatment.

Improved Safety Profile: A cleaner pharmacological profile, potentially reducing risks compared to existing options.

While we’re still in the early stages, these findings are a significant step forward in our mission to explore safer and more effective treatments for neurological conditions. We’re looking forward to the next stages of development. 💊

https://lnkd.in/e-gcU78f

#Neuroscience #Pharmaceuticals #Innovation #Ketamir2 #MentalHealth #MIRAPharma #Depression #NeuropathicPain #FDA #PTSD

We invite you to review our equity research initiation report on MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) of Miami, Florida. 

Use the link below for complimentary access!

Neurological and Neuropsychiatric Disorders to Benefit from MIRA Pharmaceuticals' Positive Discovery of Ketamir-2’s Mechanism of Action

MIRA Pharmaceuticals, a leading pre-clinical-stage pharmaceutical company, announced new insights from additional, recently received preclinical study data regarding the mechanism of action and toxicology of its novel oral ketamine analog, Ketamir-2, for neurological and neuropsychiatric disorders. This new data marks another significant step toward the Company's goal of submitting an Investigational New Drug application to the U.S. FDA for Ketamir-2 later this year.

For more details please click the link!
https://lnkd.in/gNMSjHRq 

#marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

$MIRA We are thrilled to share a recent article from Benzinga's Cannabis Capital Conference featuring MIRA Pharmaceuticals' (NASDAQ: MIRA) latest pre-clinical trial results. 
#Mentalhealth #Depression #CancerPain #PTSD #Anxiety #Suicide #Drugdiscovery #DrugDevelopment #FDA

 https://lnkd.in/da-jeNhd

Exciting News from MIRA Pharmaceuticals!
$MIRA 🚀 We are thrilled to announce a groundbreaking discovery regarding our novel drug candidate, Ketamir-2.

What’s the buzz?

🧬 Selective NMDA Inhibition: Our latest preclinical data reveals that Ketamir-2 is a selective inhibitor of the NMDA receptor at the PCP-binding site, with a 30-50-fold lower affinity compared to traditional ketamine. This unique selectivity may help reduce potential side effects like dissociation and hallucinations, ensuring a safer and more effective treatment.

Why is this important?

Reduced Side Effects: By specifically targeting the NMDA receptor, Ketamir-2 minimizes interactions with other receptors, reducing unwanted side effects often associated with ketamine.

Improved Safety Profile: Our toxicology studies in rats and dogs show no toxicity at high doses, underscoring Ketamir-2’s excellent safety margin.

Enhanced Therapeutic Effectiveness: With its selective mechanism, Ketamir-2 promises more consistent and predictable therapeutic effects, potentially revolutionizing the treatment of depression, treatment-resistant depression (TRD), and PTSD.

What’s next?

🔜 We are on track to submit an Investigational New Drug Application (IND) to the FDA later this year. This step brings us closer to starting human clinical trials and potentially offering a new standard of care for neurological and neuropsychiatric disorders.

Join us on this journey!

Follow MIRA Pharmaceuticals for more updates on our innovative research and development. Let's revolutionize mental health treatment together!

https://lnkd.in/dxM5QA4B

♻️ Repost this to spread the news and support groundbreaking medical advancements!

P.S. Have you ever heard of a drug with such a promising profile? Share your thoughts in the comments below!
#Pharmaceuticals #Mentalhealth #Drugdiscovery #Innovation #Healthcare #Medicalresearch #Neuroscience #ClinicalTrials #Biotechnology #HealthTech #DepressionTreatment #PTSD #Neuropharmacology
#HealthInnovation #ScientificBreakthrough

$MIRA Exciting News from MIRA Pharmaceuticals!

We are thrilled to announce groundbreaking preclinical results for our novel oral ketamine analog, Ketamir-2. These findings mark a significant milestone in our journey to revolutionize the treatment of neurological and neuropsychiatric disorders. 
Key Highlights: 
✅ Optimized Brain Delivery: Ketamir-2 has shown enhanced brain penetration by not interacting with P-glycoprotein (P-gp), a common barrier in drug delivery.
✅ Increased Bioavailability: Preclinical studies predict an impressive 80% oral bioavailability, compared to less than 30% for traditional ketamine. 
✅ Improved Safety Profile: Ketamir-2 potentially avoids common side effects and dependency risks associated with traditional ketamine, showing no interaction with the mu-opioid receptor. 
✅ Convenient Oral Administration: Unlike traditional ketamine, which requires IV administration, Ketamir-2’s oral formulation promises greater patient convenience and compliance. 
✅ Promising Therapeutic Potential: Ketamir-2 demonstrates significant antidepressive and anxiolytic effects, and it shows potential for lower dosing with higher efficacy.

We are also exploring the potential of Ketamir-2 for treating chemotherapy-induced depression, cancer-related neuropathic pain, and orphan drug indications like multiple sclerosis and Huntington’s disease-induced depression.

Just so you know, the results mentioned are from preclinical studies and are still under investigation. We are not making any claims regarding its safety or efficacy at this time. Ketamir-2 & Mira-55 have not been approved by the FDA, and further studies are necessary to determine their potential for human use.

#Mira #Ketamir-2 #Depression #Orphandrug #Chemo #Pain #PTSD #Drugdiscovery #Ketamin #FDA #TRD #Suicide

https://lnkd.in/enUXuFxW

$MIRA Exciting News from MIRA Pharmaceuticals! 🚀
We are thrilled to share a recent update on our research report from Zacks Investment Research that highlights more positive test results for our innovative drug candidates. These findings are a significant step forward in our mission to develop groundbreaking treatments for neurological and neuropsychiatric disorders.
Key Highlights: Our novel compounds, MIRA-55 and Ketamir-2, are showing promising results in preclinical trials. These advancements underscore our commitment to improving patient outcomes with safer, more effective therapies.

Please note: The results mentioned are from preclinical studies, and Ketamir-2 & Mira-55 is still under investigation. We are not making any claims regarding its safety or efficacy at this time. Ketamir-2 has not been approved by the FDA, and further studies are necessary to determine its potential for human use.

👉 Read the full report here
https://lnkd.in/ebbM3f6V

 #Innovation #Research #Healthcare #Neurology #MentalHealth #Pharmaceuticals #ClinicalResearch #DrugDevelopment #MIRA #Depression #Suicide #Neuropathicpain #PTSD #FDA

$MIRA  Exciting Breakthrough for MIRA Pharmaceuticals 🚀 

We are thrilled to announce the promising results of our latest preclinical studies of MIRA-55 conducted with Eurofins and Pharmaseed Ltd . These studies have shown that MIRA-55 potentially offers significant advantages over THC.

We are excited to continue our research and move closer to an Investigational New Drug (IND) application.

Please stay tuned for more updates as we move forward with our innovative treatments to improve patient outcomes.

The results mentioned are from preclinical studies and are still under investigation. We are not making any claims regarding its safety or efficacy at this time. Ketamir-2 & Mira-55 have not been approved by the FDA, and further studies are necessary to determine their potential for human use.

https://lnkd.in/gZgUgpzT

#Pharmaceuticals #Innovation #Research #Healthcare #Neurology #MiraPharmaceuticals #Mira #Pain #Cognition #Anxiety #Dementia #IND #FDA

$MIRA We're excited to share the latest research update on MIRA Pharmaceuticals by Zacks Investment Research. Discover the potential and future prospects of our groundbreaking developments. Read the full report here: https://lnkd.in/e2NDw9rP 
#DrugDevelopment #InvestorUpdate #Research #Ketamir #Mira #Cancer #Depression #Neurophatricpain #Ketamine #PTSD #TRD #FDA #IND #OralKetamine

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.

MIRA

COM:MIRAPHARMACEUTICALS

MIRA Pharmaceuticals

Last Close

1.26

22/11 21:00

Market Cap

8.27M

Beta: -

Volume Today

359.54K

Avg: -

Filings Not Available